Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy-Reference-Cited by-同舟云学术

Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy

Published:2005-09-13 Issue:4 Volume:8 Page:353-358
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Cavanaugh S X,Fuller C D,Kupelian P A,Reddy C,Bradshaw P,Pollock B H,Fuss M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/4500831.pdf

Reference26 articles.

1. Carducci MA, DeWeese TL, Nelson JB . Prostate-specific antigen and other markers of therapeutic response. Urol Clin N Am 1999; 26: 291–302, viii.

2. Montie JE . Follow-up after radical prostatectomy or radiation therapy for prostate cancer. Urol Clin N Am 1994; 21: 673–676.

3. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035–1041.

4. Small EJ, Roach III M . Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol 2002; 29: 264–273.

5. Taylor JM, Griffith KA, Sandler HM . Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 1212–1219.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients;BMC Urology;2022-11-15

2. The impact of radiation therapy on the TCR Vβ chain repertoire in patients with prostate cancer;International Journal of Oncology;2022-04-21

3. Treatment outcome and compliance to dose-intensified linac-based SBRT for unfavorable prostate tumors using a novel real-time organ-motion tracking;Radiation Oncology;2021-09-17

4. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis–Free Survival and Prostate Cancer–Specific Mortality;International Journal of Radiation Oncology*Biology*Physics;2016-11

5. High dose-rate brachytherapy boost for intermediate risk prostate cancer: Long-term outcomes of two different treatment schedules and early biochemical predictors of success;Radiotherapy and Oncology;2015-04